301 related articles for article (PubMed ID: 18931339)
1. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements.
Du HY; Pumbo E; Ivanovich J; An P; Maziarz RT; Reiss UM; Chirnomas D; Shimamura A; Vlachos A; Lipton JM; Goyal RK; Goldman F; Wilson DB; Mason PJ; Bessler M
Blood; 2009 Jan; 113(2):309-16. PubMed ID: 18931339
[TBL] [Abstract][Full Text] [Related]
2. TERT and TERC mutations detected in cryptic dyskeratosis congenita suppress telomerase activity.
Terada K; Miyake K; Yamaguchi H; Miyake N; Yamanaka K; Kojima S; Ito E; Inokuchi K; Okada T
Int J Lab Hematol; 2020 Jun; 42(3):316-321. PubMed ID: 32150348
[TBL] [Abstract][Full Text] [Related]
3. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.
Walne AJ; Vulliamy T; Beswick R; Kirwan M; Dokal I
Blood; 2008 Nov; 112(9):3594-600. PubMed ID: 18669893
[TBL] [Abstract][Full Text] [Related]
4. Proliferative defects in dyskeratosis congenita skin keratinocytes are corrected by expression of the telomerase reverse transcriptase, TERT, or by activation of endogenous telomerase through expression of papillomavirus E6/E7 or the telomerase RNA component, TERC.
Gourronc FA; Robertson mM; Herrig AK; Lansdorp PM; Goldman FD; Klingelhutz AJ
Exp Dermatol; 2010 Mar; 19(3):279-88. PubMed ID: 19558498
[TBL] [Abstract][Full Text] [Related]
5. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita.
Alter BP; Baerlocher GM; Savage SA; Chanock SJ; Weksler BB; Willner JP; Peters JA; Giri N; Lansdorp PM
Blood; 2007 Sep; 110(5):1439-47. PubMed ID: 17468339
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita.
Agarwal S
Hematol Oncol Clin North Am; 2018 Aug; 32(4):669-685. PubMed ID: 30047419
[TBL] [Abstract][Full Text] [Related]
7. The effect of TERC haploinsufficiency on the inheritance of telomere length.
Goldman F; Bouarich R; Kulkarni S; Freeman S; Du HY; Harrington L; Mason PJ; Londoño-Vallejo A; Bessler M
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17119-24. PubMed ID: 16284252
[TBL] [Abstract][Full Text] [Related]
8. Clinical mutations in the TERT and TERC genes coding for telomerase components induced oxidative stress, DNA damage at telomeres and cell apoptosis besides decreased telomerase activity.
Fernández-Varas B; Manguan-García C; Rodriguez-Centeno J; Mendoza-Lupiáñez L; Calatayud J; Perona R; Martín-Martínez M; Gutierrez-Rodriguez M; Benítez-Buelga C; Sastre L
Hum Mol Genet; 2024 Apr; 33(9):818-834. PubMed ID: 38641551
[TBL] [Abstract][Full Text] [Related]
9. Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients.
Kirwan M; Beswick R; Vulliamy T; Nathwani AC; Walne AJ; Casimir C; Dokal I
Br J Haematol; 2009 Mar; 144(5):771-81. PubMed ID: 19036115
[TBL] [Abstract][Full Text] [Related]
10. Telomere restoration and extension of proliferative lifespan in dyskeratosis congenita fibroblasts.
Westin ER; Chavez E; Lee KM; Gourronc FA; Riley S; Lansdorp PM; Goldman FD; Klingelhutz AJ
Aging Cell; 2007 Jun; 6(3):383-94. PubMed ID: 17381549
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure.
Vulliamy TJ; Walne A; Baskaradas A; Mason PJ; Marrone A; Dokal I
Blood Cells Mol Dis; 2005; 34(3):257-63. PubMed ID: 15885610
[TBL] [Abstract][Full Text] [Related]
12. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC.
Vulliamy T; Marrone A; Szydlo R; Walne A; Mason PJ; Dokal I
Nat Genet; 2004 May; 36(5):447-9. PubMed ID: 15098033
[TBL] [Abstract][Full Text] [Related]
13. Dyskeratosis congenita, stem cells and telomeres.
Kirwan M; Dokal I
Biochim Biophys Acta; 2009 Apr; 1792(4):371-9. PubMed ID: 19419704
[TBL] [Abstract][Full Text] [Related]
14. Dyskeratosis congenita: telomerase, telomeres and anticipation.
Marrone A; Walne A; Dokal I
Curr Opin Genet Dev; 2005 Jun; 15(3):249-57. PubMed ID: 15917199
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow failure and the new telomere diseases: practice and research.
Young NS
Hematology; 2012 Apr; 17 Suppl 1():S18-21. PubMed ID: 22507770
[TBL] [Abstract][Full Text] [Related]
16. HuR regulates telomerase activity through TERC methylation.
Tang H; Wang H; Cheng X; Fan X; Yang F; Zhang M; Chen Y; Tian Y; Liu C; Shao D; Jiang B; Dou Y; Cong Y; Xing J; Zhang X; Yi X; Songyang Z; Ma W; Zhao Y; Wang X; Ma J; Gorospe M; Ju Z; Wang W
Nat Commun; 2018 Jun; 9(1):2213. PubMed ID: 29880812
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders.
Balakumaran A; Mishra PJ; Pawelczyk E; Yoshizawa S; Sworder BJ; Cherman N; Kuznetsov SA; Bianco P; Giri N; Savage SA; Merlino G; Dumitriu B; Dunbar CE; Young NS; Alter BP; Robey PG
Blood; 2015 Jan; 125(5):793-802. PubMed ID: 25499762
[TBL] [Abstract][Full Text] [Related]
18. The relationship between DNA methylation and telomere length in dyskeratosis congenita.
Gadalla SM; Katki HA; Shebl FM; Giri N; Alter BP; Savage SA
Aging Cell; 2012 Feb; 11(1):24-8. PubMed ID: 21981348
[TBL] [Abstract][Full Text] [Related]
19. Robust DNA Damage Response and Elevated Reactive Oxygen Species in TINF2-Mutated Dyskeratosis Congenita Cells.
Pereboeva L; Hubbard M; Goldman FD; Westin ER
PLoS One; 2016; 11(2):e0148793. PubMed ID: 26859482
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations.
Marrone A; Sokhal P; Walne A; Beswick R; Kirwan M; Killick S; Williams M; Marsh J; Vulliamy T; Dokal I
Haematologica; 2007 Aug; 92(8):1013-20. PubMed ID: 17640862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
